Hypothalamic obesity after craniopharyngioma: Mechanisms, diagnosis, and treatment

Frontiers in Endocrinology

Volumn 2, Issue NOV, 2011, Pages

  Lustig, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Craniopharyngioma; Ghrelin; Hypothalamic obesity; Insulin; Leptin resistance; Octreotide; Symap thetic nervous system; Vagus nerve

Indexed keywords

EID: 84872437765     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2011.00060     Document Type: Review

References (85)

1. al-Adsani, H., Hoffer, L. J., and Silva, J. E. (1997). Resting energy expen-diture is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J. Clin. Endocrinol. Metab. 82, 1118-1125.
2. Arbuzova, A., Murray, D., and McLaughlin, S. (1998). MARCKS, membranes, and calmodulin: kinet-ics of their interaction. Biochim. Biophys. Acta 1376, 369-379.
3. Babinski, M. J. (1900). Tumeur du corps pituitaire san acromegalie et avec arret de developpement des organes genitaux. Rev. Neurol. 8, 531-533.
4. Balthasar, N., Dalgaard, L. T., Lee, C. E., Yu, J., Funahashi, H., Williams, T., Ferreira, M., Tang, V., McGov-Ern,R. A.,Kenny,C. D.,Christiansen, L. M., Edelstein, E., Choi, B., Boss, O., Aschkenasi, C., Zhang, C. Y., Mountjoy, K., Kishi, T., Elmquist, J. K., and Lowell, B. B. (2005). Divergence of melanocortin path-ways in the control of food intake and energy expenditure. Cell 123, 493-505.
5. Berthoud, H. R., and Jeanrenaud, B. (1979). Acute hyperinsulinemia and its reversal by vagotomy following lesions of the ven-tromedial hypothalamus in anesthetized rats. Endocrinology 105, 146-151.
6. Blaak, E. E., Saris, W. H., and van Baak, M. A. (1993). Adrenoceptor subtypes mediating catecholamine-induced thermogenesis in man. Int. J. Obes. 17, S78-S81.
7. 2+ store in secretory granules of insulin-producing cells. J. Biol. Chem. 269, 27167-27170.
8. Boden, G., and Hoeldtke, R. D. (2003). Nerves, fat, and insulin resistance. N. Engl.J.Med.349, 1966-1967.
9. g coactivator-1. Biochem. Biophys. Res. Commun. 261, 870-876.
10. Bray, G. A. (1984). Syndromes of hypo-thalamic obesity in man. Pediatr. Ann. 13, 525-536.
11. Bray, G. A., and Gallagher, T. F. (1975). Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine (Baltimore) 54, 301-333.
12. Bray, G. A., Inoue, S., and Nishizawa, Y. (1981). Hypothalamic obesity. Diabetologia 20, 366-377.
13. Bray, G. A., and Nishizawa, Y. (1978). Ventromedial hypothalamus modulates fat mobilization during fasting. Nature 274, 900-902.
14. Collins, S., Kuhn, C. M., Petro, A. E., Swick, A. G., Chrunyk, B. A., and Surwit, R. S. (1996). Role of leptin in fat regulation. Nature 380, 677.
15. Coutant, R., Maurey, H., Rouleau, S., Mathieu, E., Mercier, P., Limal, J. M., and Le Bouil, A. (2003). Defect in epinephrine production in children with craniopharyngioma: functional or organic origin? J. Clin. Endocrinol. Metab. 88, 5969-5975.
16. D'Alessio, D. A., Kieffer, T. J., Taborsky, G. J., and Havel, P. J. (2001). Activa-tion of the parasympathetic nervous system is necessary for normal meal induced-insulin secretion in rhesus macaques. J. Clin. Endocrinol. Metab. 86, 1253-1259.
17. Danielsson, P., Janson, A., Norgren, S., and Marcus, C. (2007). Impact sibutramine therapy in children with hypothalamic obesity or obe-sity with aggravating syndromes. J. Clin. Endocrinol. Metab. 92, 4101-4106.
18. Daousi, C., Dunn, A. J., Foy, P. M., MacFarlane, I. A., and Pinkney, J. H. (2005). Endocrine and neu-roanatomic predictors of weight gain and obesity in adult patients with hypothalamic damage. Am. J. Med. 118, 45-50.
19. Elmquist, J. K., Ahima, R. S., Elias, C. F., Flier, J. S., and Saper, C. B. (1998). Leptin activates distinct pro-jections from the dorsomedial and ventromedial hypothalamic nuclei. Proc. Natl. Acad. Sci. U.S.A. 95, 741-746.
20. Elmquist, J. K., Elias, C. F., and Saper, C. B. (1999). From lesions to lep-tin: hypothalamic control of food intake and body weight. Neuron 22, 221-232.
21. Frohlich, A. (1901). Ein fall von tumor der hypophysis cerebri ohne akromegalie. Weiner Klin. Rundsch. 15, 883-886.
22. Gilon, P., and Henquin, J. C. (2001). Mechanisms and physiological sig-nificance of the cholinergic control of pancreatic β-cell function. Endocr. Rev. 22, 565-604.
23. Hamilton, J. K., Conwell, L. S., Syme, C., Ahmet, A., Jeffery, A., and Dane-Man, D. (2011). Hypothalamic obe-sity following craniopharyngioma surgery: results of a pilot trial of combined diazoxide and metformin therapy. Int. J. Pediatr. Endocrinol. 2011, 417949.
24. Harz, K. J., Muller, H. L., Waldeck, E., Pudel, V., and Roth, C. (2003). Obesity in patients with cran-iopharyngioma: assessment of food intake and movement counts indicating physical activity. J. Clin. Endocrinol. Metab. 88, 5227-5231.
25. Inge, T. H., Pfluger, P., Zeller, M., Rose, S. R., Burget, L., Sundarara-Jan, S., Daniels, S. R., and Tschöp, M. H. (2007). Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat. Clin. Pract. Endocrinol. Metab. 3, 606-609.
26. Jeanrenaud, B. (1985). An hypothesis on the aetiology of obesity: dysfunction of the central nervous system as a primary cause. Diabetologia 28, 502-513.
27. Kalra, S. P., Dube, M. G., Pu, S., Xu, B., Horvath, T. L., and Kalra, P. S. (1999). Interacting appetite-regulating pathways in the hypo-thalamic regulation of body weight. Endocr. Rev. 20, 68-100.
28. Kamegai, J., Tamura, H., Shimizu, T., Ishii, S., Sugihara, H., and Wak-Abayashi, I. (2000). Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypo-thalamic peptide gene expression. Endocrinology 141, 4797-4800.
29. Karavitaki, N., Cudlip, S., Adams, C. B., and Wass, J. A. (2006). Cran-iopharyngiomas. Endocr. Rev. 27, 371-397.
30. Kiefer, T. J., and Habener, J. F. (1999). The glucagon-like peptides. Endocr. Rev. 20, 876-913.
31. Komeda, K., Yokote, M., and Oki, Y. (1980). Diabetic syndrome in the Chinese hamster induced with monosodium glutamate. Experien-tia 36, 232-234.
32. Lowell, B. B., and Spiegelman, B. M. (2000). Towards a molecular under-standing of adaptive thermogenesis. Nature 404, 652-660.
33. Lustig,R. H. (2002). Hypothalamic obesity: the sixth cranial endocrinopathy. Endocrinologist 12, 210-217.
34. Lustig, R. H. (2003). Autonomic dys-function of the (ß-cell and the pathogenesis of obesity. Rev. Endocr. Metab. Disord. 4, 23-32.
35. Lustig, R. H. (2006). Childhood obesity: behavioral aberration or biochemi-cal drive? Reinterpreting the first law of thermodynamics. Nat. Clin. Pract. Endocrinol. Metab. 2, 447-458.
36. Lustig, R. H. (2007). "The efferent arm of the energy balance regulatory pathway: neuroendocrinology and pathology," in Obesity and Energy Metabolism: Research and Clinical Applications, ed. P. A. Donahoue (Totowa, NJ: Humana), 69-86.
37. Lustig, R. H., Post, S. M., Srivanna-boon, K., Rose, S. R., Danish, R. K., Burghen, G. A., Xiong, X., Wu, S., and Merchant, T. E. (2003a). Risk factors for the development of obesity in children surviving brain tumors. J. Clin. Endocrinol. Metab. 88, 611-616.
38. Lustig, R. H., Hinds, P. S., Ringwald-Smith, K., Christensen, R. K., Kaste, S. C., Schreiber, R. E., Rai, S. N., Lensing, S. Y., Wu, S., and Xiong, X. (2003b). Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 88, 2586-2592.
39. Lustig, R. H., Rose, S. R., Burghen, G. A., Velasquez-Mieyer, P., Broome, D. C., Smith, K., Li, H., Hudson, M. M., Heideman, R. L., and Kun, L. E. (1999). Hypothalamic obesity in children caused by cranial insult: altered glucose and insulin dynamics, and reversal by a somatostatin agonist. J. Pediatr. 135, 162-168.
40. Lustig, R. H., Tsai, P., Hirose, S., and Farmer, D. L. (2009). "Treatment of hypothalamic obesity by laparoscopic truncal vagotomy: early experience," in Proceedings of the 8th Lawson Wilkins/European Pediatric Endocrine Society meeting.NewYork, NY.
41. Marin, P., Russeffé-Scrive, A., Smith, J., and Bjorntorp, P. (1988). Glu-cose uptake in human adipose tissue. Metab. Clin. Exp. 36, 1154-1164.
42. Mason, P. W., Krawiecki, N., and Meacham, L. R. (2002). The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch. Pediatr. Adolesc. Med. 156, 887-892.
43. Matsuda, M., and DeFronzo, R. A. (1999). Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462-1470.
44. Merchant, T. E., Kienha, E. N., San-Ford, R. A., Mulhern, R. K., Thomp-Son, S. J., Wilson, M. W., Lustig, R. H., and Kun, L. E. (2002). Craniopharyngioma: the St. Jude Chil-dren's Research Hospital experience 1984-2001. Int. J. Radiat. Oncol. Biol. Phys. 53, 533-542.
45. 2+ pools. Biochem. Biophys. Res. Commun. 224, 67-73.
46. Molloy, P. T., Berkowitz, R., Stallings, V. A., Krell, H., Sutton, L. N., Vaughan, S. N., Loeb, N., and Phillips, P. C. (1998). "Pilot study of evaluation and treatment of tumor-related obesity in pediatric patients with hypothalamic/chiasmatic gliomas and craniopharyngiomas," in Proceedings of the International Pediatric Oncology Meeting, Rome, 156.
47. Müller, H. L., Gebhardt, U., Wessel, V., Schröder, S., Kolb, R., Sörensen, N., Maroske, J., and Hanisch, E. (2007). First experiences with laparoscopic adjustable gastric banding (LAGB) in the treatment of patients with childhood craniopharyngioma and morbid obesity. Klin. Padiatr. 219, 323-325.
48. Muller, H. L. (2008). Childhood craniopharyngioma: recent advances in diagnosis, treatment and follow-up. Horm. Res. 69, 193-202.
49. Muller, H. L., Emser, A., Faldum, A., Bruhnken, G., Etavard-Gorris, N., Gebhardt, U., Oeverink, R., Kolb, R., and Sörensen, N. (2004). Longitudinal study of growth and body mass index before and after diagnosis of childhood craniopharyngioma. J. Clin. Endocrinol. Metab. 89, 3298-3305.
50. Müller, H. L., Gebhardt, U., Teske, C., Faldum, A., Zwiener, I., Warmuth-Metz, M., Pietsch, T., Pohl, F., Sörensen, N., Calaminus, G., and Study Committee of KRANIOPHA-RYNGEOM 2000. (2011). Post-operative hypothalamic lesions and obesity in childhood craniopharyn-gioma: results of the multina-tional prospective trial KRANIO-PHARYNGEOM 2000 after 3-year follow-up. Eur. J. Endocrinol. 165, 17-24.
51. Muntzel, M., Morgan, D. A., Mark,A. L., and Johnson, A. K. (1994). Intrac-erebroventricular insulin produces non-uniform regional increases in sympathetic nerve activity. Am. J. Physiol. 267, R1350-R1355.
52. Nishi, S., Seino, Y., Ishida, H., Seno, M., Taminato, T., Sakurai, H., and Imura,H. (1987).Vagal regulation of insulin, glucagon, and somatostatin secretion in vitro in the rat. J. Clin. Invest. 79, 1191-1196.
53. O'Gorman, C. S., Simoneau-Roy, J., Pencharz, P., Adeli, K., and Hamil-Ton, J. (2911). Delayed ghrelin suppression following oral glucose tolerance test in children and adolescents with hypothalamic injury secondary to craniopharyngioma compared with obese controls. Int. J. Pediatr. Obes. 6, 285-288.
54. O'Gorman, C. S., Simoneau-Roy, J., Pencharz, P., MacFarlane, J., MacLusky, I., Narang, I., Adeli, K., Daneman, D., and Hamilton, J. (2010). Sleep-disordered breathing is increased in obese adolescents with craniopharyngioma compared with obese controls. J. Clin. Endocrinol. Metab. 95, 2211-2218.
55. Peles, E., Goldstein, D. S., Akselrod, S., Nitzan, H., Azaria, M., Almog, S., Dolphin, D., Halkin, H., and Modan, M. (1995). Interrelationships among measures of autonomic activity and cardiovascular risk factors during orthostasis and the oral glucose tolerance test. Clin. Auton. Res. 5, 271-278.
56. Pinto, G., Bussieres, L., Recasens, C., Souberbielle, J. C., Zerah, M., and Brauner, R. (2000). Hormonal factors influencing weight and growth pattern in craniopharyngioma. Horm. Res. 53, 163-169.
57. Powley, T. L., and Laughton, W. (1981). Neural pathways involved in the hypothalamic integration of autonomic responses. Diabetologia 20, 378-387.
58. Preeyasombat, C., Bacchetti, P., Lazar,A. A., and Lustig, R. H. (2005). Racial and etiopathologic dichotomies in insulin secretion and resistance in obese children. J. Pediatr. 146, 474-481.
59. Rahmouni, K., Haynes, W. G., Mor-Gan, D. A., and Mark, A. L. (2003). Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin. J. Neurosci. 23, 5998-6004.
60. Rakhshani, N., Jeffery, A. S., Schulte, F., Barrera, M., Atenafu, E. G., and Hamilton, J. K. (2010). Evaluation of a comprehensive care clinic model for children with brain tumor and risk for hypothalamic obesity. Obesity (Silver Spring) 18, 1768-1774.
61. Rogers, P. C., Meacham, L. R., Oeffin-Ger, K. C., Henry, D. W., and Lange, B. J. (2005). Obesity in pediatric oncology. Pediatr. Blood Cancer 45, 881-891.
62. Rohner-Jeanrenaud, F., and Jeanrenaud, B. (1980). Consequences of ventromedial hypothalamic lesions upon insulin and glucagon secretion by subsequently isolated perfused pan-creases in the rat. J. Clin. Invest. 65, 902-910.
63. Rohner-Jeanrenaud, F., and Jeanre-Naud, B. (1985). Involvement of the cholinergic system in insulin and glucagon oversecretion of genetic preobesity. Endocrinology 116, 830-834.
64. Roth, C. L., Hunneman, D. H., Gebhardt, U., Stoffel-Wagner, B., Reinehr, T., and Müller, H. L. (2007). Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma. Pediatr. Res. 61, 496-501.
65. Satoh, N., Ogawa, Y., Katsura, G., Tsuji, T., Masuzaki, H., Hiraoka, J., Okazaki, T., Tamaki, M., Hayase, M., Yoshimasa, Y., Nishi, S., Hosoda, K., and Nakao, K. (1997). Pathophys-iological significance of the obese gene product, leptin in ventrome-dial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats. Endocrinology 138, 947-954
66. Schofl, C., Schleth, A., Berger, D., Terkamp, C., Von Zur Muhlen, A., and Brabant, G. (2002). Sympathoadrenal counterregulation in patients with hypothalamic craniopharyngioma. J. Clin. Endocrinol. Metab. 87, 624-629.
67. Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., and Baskin, D. G. (2000). Central nervous system control of food intake. Nature 404, 661-671.
68. Shaikh, M. G., Grundy, R. G., and Kirk, J. M. (2008). Reductions in basal metabolic rate and physical activity contribute to hypothalamic obesity. J. Clin. Endocrinol. Metab. 93, 2588-2593.
69. Sharp, G. W. (1996). Mechanisms of inhibition of insulin release. Am. J. Physiol. 271, C1781-C1799.
70. Simoneau-Roy, J., O'Gorman, C., Pen-Charz, P., Adeli, K., Daneman, D., and Hamilton, J. (2010). Insulin sensitivity and secretion in children and adolescents with hypothalamic obesity following treatment for craniopharyngioma. Clin. Endocrinol. (Oxf) 72, 364-370.
71. Sluiter, W. J., Erkelens, D. W., Terp-Stra, P., Reitsma, W. D., and Doorendos, H. (1976). Glucose intolerance and insulin release, a mathematical approach.1. Assay of the beta cell response after glucose loading. Diabetes 25, 241-244.
72. Small, C. J., and Bloom, S. R. (2004). Gut hormones and the control of appetite. Trends Endocrinol. Metab. 15, 259-263.
73. Smith, D. K., Sarfeh, J., and Howard, L. (1983). Truncal vagotomy in hypothalmic obesity. Lancet 1, 1330-1331.
74. Sorva, R. (1988). Children with craniopharyngioma: early growth failure and rapid post-operative weight gain. Acta Paediatr. Scand. 77, 587-592.
75. Spoudeas, H. A., Saran, F., and Pizer, B. (2006). A multimodality approach to the treatment of craniopharyngiomas avoiding hypothalamic morbidity: a UK perspective. J. Pediatr. Endocrinol. Metab. 19, 447-451.
76. Srinivasan, S., Ogle, G. D., Garnett, S. P., Briody, J. N., Lee, J. W., and Cowell, C. T. (2004). Features of the meta-bolic syndrome after craniopharyn-gioma. J. Clin. Endocrinol. Metab. 89, 81-86.
77. Stahnke, N., Grubel, G., Lagenstein, I., and Willig, R. P. (1984). Long-term follow-up of children with cranio-pharyngioma. Eur. J. Pediatr. 142, 179-185.
78. Susulic, V. S., Frederich, R. C., Lawitts, J., Tozzo, E., Kahn, B. B., Harper, M. E., Himms-Hagen, J., Flier, J. S., and Lowell, B. B. (1995). Targeted disruption of the beta 3-adrenergic receptor gene. J. Biol. Chem. 270, 29483-29492.
79. Tian, Y. M., Urquidi, V., and Ashcroft, S. J. H. (1996). Protein kinase C in β-cells: expression of multiple isoforms and involvement in cholinergic stimulation of insulin secretion. Mol. Cell. Endocrinol. 119, 185-193.
80. Tiosano, D., Eisenstein, I., Militianu, D., Chrousos, G. P., and Hochberg, Z. (2003). 11β-hydroxysteroid dehy-drogenase activity in hypothalamic obesity. J. Clin. Endocrinol. Metab. 88, 384.
81. Tschöp, M., Smiley, D. L., and Heiman, M. L. (2000). Ghrelin induces adiposity in rodents. Nature 407, 908-913.
82. Viguerie, N., Clement, K., Barbe, P., Courtine, M., Benis, A., Larrouy, D., Hanczar, B., Pelloux, V., Poitou, C., Khalfallah, Y., Barsh, G. S., Thala-Mas, C., Zucker, J. D., and Langin, D. (2004). In vivo epinephrine-mediated regulation of gene express in human skeletal muscle. J. Clin. Endocrinol. Metab. 89, 2000-2014.
83. Vinchon, M., Weill, J., Delestret, I., and Dhellemmes, P. (2009). Craniopharyngioma and hypothalamic obesity in children. Childs Nerv. Syst. 25, 347-352.
84. Vollenweider, L., Tappy, L., Owlya, R., Jequier, E., Nicod, P., and Scherrer, U. (1995). Insulin-induced sympathetic activation and vasodilation in skeletal muscle. Effects of insulin resistance in lean subjects. Diabetes 44, 641-645.
85. Zawalich, W. S., Zawalich, K. C., and Rasmussen, H. (1989). Cholinergic agonists prime the β-cell to glucose stimulation. Endocrinology 125, 2400-2406